Novartis had once hoped aliskiren would be a key driver of sales growth, but the company this week said the drug, which had sales of $449 million in the first nine months of the year, is likely to be "negatively impacted" by the poor trial results. ❋ Jeanne Whalen (2011)
Novartis said that the revamp plan has been accelerated after a recent clinical study flagged potential safety problems with aliskiren, prompting the company to cease promotion for the product for some patients. ❋ Neil MacLucas (2012)
A charge of $160 million will be booked in the first quarter, while the lower sales potential of aliskiren will lead to a fourth-quarter charge of $900 million, it said in a statement Friday. ❋ Neil MacLucas (2012)
The trial had been testing aliskiren in 8,600 patients with type 2 diabetes and poor kidney function, who because of their conditions are "known to be at a high risk of cardiovascular and renal" problems, Novartis said. ❋ Jeanne Whalen (2011)
Novartis said it will stop promoting aliskiren for use in combination with ACE-inhibitors and angiotensin receptor blockers until regulators decide whether the drug's marketing license needs to be changed. ❋ Jeanne Whalen (2011)
ZURICH— Novartis AG Friday said it will cut 1,960 jobs as it restructures its U.S. business, reflecting the patent loss of heart drug Diovan in the U.S. and the recent failure to turn high blood pressure medicine aliskiren into a blockbuster. ❋ Neil MacLucas (2012)
Earlier this week, Novartis said it was stopping a large clinical trial of aliskiren on the advice of an independent safety monitoring board, which identified higher rates of nonfatal stroke, renal complications and other problems in patients taking aliskiren. ❋ Jeanne Whalen (2011)
Europe's main drug regulator said it was starting a review of the Novartis AG hypertension pill aliskiren after a large clinical trial linked the drug to possible risks of nonfatal stroke and kidney problems. ❋ Jeanne Whalen (2011)
Patients in the study were given either aliskiren or a placebo pill in addition to the blood-pressure medication they were already taking—either an ACE inhibitor or an angiotensin receptor blocker. ❋ Jeanne Whalen (2011)
Europe's main drug regulator is starting a review of the Novartis hypertension pill aliskiren after a large clinical trial linked the drug to possible risks of nonfatal stroke and kidney problems. ❋ Unknown (2011)
Novartis presented data on aliskiren, its new pill for high blood pressure. ❋ Unknown (2006)
Alan Gradman, a cardiologist at Temple University who has led some trials of aliskiren, says there may be a bigger potential for the drug: It could help prevent damage to organ systems like the kidneys. ❋ Unknown (2006)
Tekturna HCT ®, a single-pill combination of aliskiren and hydrochlorothiazide HCT, was approved in the US in 2008 for second-line treatment of high blood pressure, and in 2009 for first-line treatment of high blood pressure. ❋ Unknown (2011)
It shows that starting treatment with the two drugs aliskiren and amlodipine in a combination pill reduced blood pressure on average by 25 per cent more than one drug. ❋ Unknown (2011)
The pill aims to treat high blood pressure that is not adequately controlled by either aliskiren or amlodipine alone.
Rasitrio is indicated for the treatment of hypertension in patients who can be adequately treated with aliskiren, amlodipine and hydrochlorothiazide given at the same time and dose level as in the combination. ❋ Unknown (2011)
The triple combination of aliskiren, amlodipine and hydrochlorothiazide HCT, was approved in the United States in December 2010 under the trade name Amturnide The European Commission generally follows the recommendations of the CHMP and delivers its final decision within three months of the CHMP recommendation. ❋ Unknown (2011)
Rasitrio aliskiren, amlodipine and hydrochlorothiazide Tablets Prescribing Information. ❋ Unknown (2011)
The US Food and Drug Administration (FDA) has approved Valturna ((R)) (aliskiren and valsartan) table ... ❋ Editors (2010)
However, our results show that the addition of aliskiren to standard therapy in high-risk post-MI patients does not affect left ventricular size or function. ❋ Unknown (2010)
